Bionano Genomics, Inc. (NASDAQ:BNGO) Stock Position Lifted by GSA Capital Partners LLP

GSA Capital Partners LLP lifted its holdings in Bionano Genomics, Inc. (NASDAQ:BNGO) by 532.7% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 549,789 shares of the company’s stock after purchasing an additional 462,887 shares during the quarter. GSA Capital Partners LLP owned 0.82% of Bionano Genomics worth $610,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Quadrature Capital Ltd acquired a new stake in shares of Bionano Genomics in the fourth quarter valued at $209,000. Headlands Technologies LLC acquired a new stake in shares of Bionano Genomics in the fourth quarter valued at $72,000. Carret Asset Management LLC acquired a new stake in shares of Bionano Genomics in the fourth quarter valued at $34,000. Finally, Cantor Fitzgerald L. P. lifted its holdings in shares of Bionano Genomics by 22.2% in the fourth quarter. Cantor Fitzgerald L. P. now owns 55,000 shares of the company’s stock valued at $104,000 after buying an additional 10,000 shares during the period. Institutional investors own 11.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, BTIG Research cut their price objective on Bionano Genomics from $3.00 to $2.00 and set a “buy” rating for the company in a report on Thursday, May 16th.

Bionano Genomics Trading Up 4.3 %

Shares of NASDAQ BNGO opened at $0.65 on Friday. Bionano Genomics, Inc. has a 12 month low of $0.52 and a 12 month high of $6.76. The company has a market cap of $43.75 million, a price-to-earnings ratio of -0.11 and a beta of 2.40. The company has a quick ratio of 1.13, a current ratio of 1.46 and a debt-to-equity ratio of 0.04. The business has a fifty day simple moving average of $0.86 and a 200-day simple moving average of $1.07.

Bionano Genomics (NASDAQ:BNGO) last announced its earnings results on Wednesday, May 8th. The company reported ($0.60) EPS for the quarter. Bionano Genomics had a negative net margin of 605.26% and a negative return on equity of 129.31%. The company had revenue of $8.77 million for the quarter. Sell-side analysts predict that Bionano Genomics, Inc. will post -1.87 EPS for the current year.

About Bionano Genomics

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.